{"nctId":"NCT00392288","briefTitle":"Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.","startDateStruct":{"date":"2006-09"},"conditions":["Asthma"],"count":528,"armGroups":[{"label":"Placebo MDI","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Ciclesonide MDI 40 µg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Ciclesonide"]},{"label":"Ciclesonide MDI 80 µg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Ciclesonide"]}],"interventions":[{"name":"Ciclesonide","otherNames":[]},{"name":"Ciclesonide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of persistent bronchial asthma for at least 3 months prior to screening;\n* For patients with persistent bronchial asthma and being treated with a controller therapy: Documented use of an inhaled steroid or Singulair® 5mg once daily;\n* For patients with persistent bronchial asthma and not being treated with controller therapy: Patients may have documented use of a reliever therapy such as albuterol/salbutamol or may be untreated;\n* Morning Peak Expiratory Flow (AM PEF) of ≤90% of predicted values from the in-clinic spirometry after a 6 hour withhold of albuterol/salbutamol;\n* Only patients aged between 6 to \\<12 years must have a forced expiratory volume in one second (FEV1) of ≥50% to ≤85% of predicted normal after a 6 hour withhold of albuterol/salbutamol\n\nExclusion Criteria:\n\n* Nocturnal awakenings for asthma which require treatment with albuterol/salbutamol for 4 or more nights out of the last 7 days of the screening period;\n* Use of more than 8 puffs/day of albuterol/salbutamol on 3 or more consecutive days within the last 7\n* Upper or lower respiratory tract infection within 4 weeks prior to screening and during screening period;\n* History of life-threatening asthma, including a history of significant hypercarbia (pCO2 \\>45 mmHg), prior intubation, respiratory arrest, or seizures as a result of an exacerbation of asthma;\n* More than 3 in-patient hospitalization or emergency care visits due to asthma exacerbations in the year prior to screening;\n* Use of injectable or oral corticosteroids within one month prior to screening, or more than 3 bursts) within 6 months prior to screening;","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12.","description":"Change in FEV1 (Percent of predicted) from baseline to week 12. FEV1 was measured only in children between 6 to \\<12 years only. Least Squares Mean were adjusted for Baseline FEV1, age \\[yrs\\], pooled center, previous corticosteroid therapy and holding chamber.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"1.06"},{"groupId":"OG001","value":"5.3","spread":"1.06"},{"groupId":"OG002","value":"7.7","spread":"1.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Daily Asthma Symptom Score at Week 12.","description":"Change in total daily asthma symptom score from baseline to week 12. 5-Point, ordinal scale specifying patient's experience of symptoms during day and night from 0 (no symptoms) to 4 (symptoms that prevent the patient from engaging in daily activities or sleep)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"0.08"},{"groupId":"OG001","value":"-1.13","spread":"0.08"},{"groupId":"OG002","value":"-0.99","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Use of Albuterol/Salbutamol at Week 12.","description":"Change in albuterol/salbutamol use from baseline to week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.59","spread":"0.08"},{"groupId":"OG001","value":"-0.87","spread":"0.08"},{"groupId":"OG002","value":"-0.93","spread":"0.08"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":172},"commonTop":["Asthma","Pharyngitis","Headache","Upper respiratory tract infection","Nasopharyngitis"]}}}